Mercury Laboratories declares ₹3.5 per share final dividend for FY26

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights

Mercury Laboratories declared a ₹3.5 per share final dividend for FY26, subject to AGM approval. With a record date of September 21, 2026, the company emphasized strict adherence to TDS norms under the Income Tax Act, 2025. Residents face a 10% TDS unless exempt, while non-residents must provide DTAA documents to claim treaty benefits. Electronic payment mandates require immediate KYC updates.

powered bylight_fuzz_icon
48776017

*this image is generated using AI for illustrative purposes only.

Mercury Laboratories has declared a final dividend of ₹3.5 per equity share for the financial year ended March 31, 2026 (FY26). The Board of Directors recommended this payout during its meeting held on May 29, 2026, pending approval from shareholders at the ensuing Annual General Meeting (AGM).

The company has designated Monday, September 21, 2026 as the record date to determine eligibility for the dividend. In line with regulatory mandates requiring electronic dividend payments, shareholders must ensure their bank account details, including IFSC codes, are updated with their Depository Participants or the Registrar and Share Transfer Agent.

Tax Deduction at Source (TDS) Implications

Under the prevailing provisions of the Income Tax Act, 2025, Mercury Laboratories will deduct tax at source on dividend payouts. The applicable TDS rates vary based on the shareholder's residential status and submitted documentation:

Shareholder Category: Applicable TDS Rate: Key Requirements
Resident Individuals 10% Exempt if aggregate dividend ≤ ₹10,000; Form 121 required for nil deduction
Resident Entities (MFs/AIFs) Nil Documentary evidence of exemption status under Schedule VII
Non-Residents (FII/FPI) 20% + surcharge/cess DTAA benefits available via Form 41 and Tax Residency Certificate

Resident individual shareholders can avoid TDS if their total dividend income from the company does not exceed ₹10,000 in the tax year 2026-2027. Those eligible for lower or nil rates must submit a self-attested certificate under Section 395 of the Act. Failure to link Aadhaar with PAN may result in TDS at a higher rate of 20%.

Compliance and Documentation

Non-resident shareholders seeking benefits under Double Taxation Avoidance Agreements (DTAA) must submit specific documents by the record date. These include a self-attested PAN, Tax Residency Certificate (TRC), and e-filed Form 41. The company reserves the right to apply standard TDS rates if documentation is incomplete or unsatisfactory.

Shareholders holding shares in physical mode must submit service requests along with cancelled cheques and PAN copies to the Registrar. Demat holders must update details directly with their Depository Participants. No claims against the company will be entertained for taxes deducted due to missing or inaccurate information.

Historical Stock Returns for Mercury Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.27%+0.58%-11.33%-6.63%-9.00%+10.59%

How might Mercury Laboratories' dividend payout ratio for FY26 compare to its historical averages and peer companies in the pharmaceutical sector?

What impact could the mandatory TDS deductions have on the net yield for non-resident investors relying on DTAA benefits, given the strict documentation deadlines?

Will the Board of Directors propose any additional capital allocation strategies, such as share buybacks or reinvestment in R&D, alongside this dividend declaration?

Mercury Laboratories Q1FY26 net profit falls 69% to ₹30 lakh on revenue drop

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

Mercury Laboratories' Q1FY26 net profit fell 69% YoY to ₹29.78 lakh due to a 12% revenue drop to ₹1,596.32 lakh and a sharp decline in other income. Expenses decreased by 6.8% but were insufficient to offset the top-line contraction.

powered bylight_fuzz_icon
46508033

*this image is generated using AI for illustrative purposes only.

Mercury Laboratories Limited reported a sharp decline in profitability for the quarter ended June 30, 2026, with net profit after tax falling 69% year-on-year to ₹29.78 lakh. Revenue from operations contracted 12% to ₹1,596.32 lakh compared to ₹1,813.54 lakh in the same period last year, signaling margin pressure as cost reductions failed to offset lower top-line growth.

The results were approved by the Board of Directors at a meeting held on July 25, 2026, in Vadodara, and reviewed by the Audit Committee. The unaudited financial statements were filed with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Newspaper advertisements containing the quick response (QR) code for accessing full results were published in Active Times (English) and Mumbai Lakshdeep (Marathi), as notified under Regulation 47 of the SEBI LODR Regulations, 2015.

Total income for the quarter stood at ₹1,601.54 lakh, down from ₹1,831.64 lakh in Q1FY25. Other income decreased significantly to ₹5.22 lakh from ₹18.10 lakh in the corresponding period last year. Total expenses were recorded at ₹1,562.35 lakh, lower than the ₹1,676.91 lakh incurred in Q1FY25, primarily due to reduced material costs. However, this reduction was insufficient to counteract the revenue decline.

Financial Performance Highlights

Particulars Q1FY26 (₹ in lakhs) Q1FY25 (₹ in lakhs) Change (%)
Revenue from Operations 1,596.32 1,813.54 -12.0%
Other Income 5.22 18.10 -71.2%
Total Income 1,601.54 1,831.64 -12.6%
Total Expenses 1,562.35 1,676.91 -6.8%
Profit Before Tax 39.19 154.73 -74.7%
Net Profit After Tax 29.78 96.76 -69.2%
EPS (Basic & Diluted) 2.48 8.06 -69.2%

What the Numbers Show

The divergence between revenue decline and expense management reveals significant margin compression. While total expenses decreased by 6.8% year-on-year, revenue fell by a sharper 12%, leading to a compressed operating buffer. Cost of materials consumed dropped slightly to ₹579.14 lakh from ₹593.83 lakh, but this was not enough to counteract the lower sales volume. Employee benefits expense remained relatively stable at ₹423.64 lakh, indicating fixed cost rigidity despite lower operational throughput. The significant drop in other income further exacerbated the bottom-line impact, suggesting that non-operating gains cannot compensate for core business slowdowns.

The financial results were prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013. Naresh & Co., the statutory auditors, conducted a limited review in accordance with Standard on Review Engagement (SRE) 2410. CA Abhijeet Dandekar, Partner at Naresh & Co., signed the review report, stating that nothing came to their attention to suggest the statement contained material misstatements or failed to disclose required information.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE947G01011/5d058be7-eac2-4168-a5bb-7fda89c2309d.pdf

Historical Stock Returns for Mercury Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.27%+0.58%-11.33%-6.63%-9.00%+10.59%

What specific strategic initiatives is Mercury Laboratories planning to implement to reverse the 12% revenue decline and stabilize top-line growth in upcoming quarters?

How does the current margin compression compare to industry peers, and what competitive pressures are driving the inability of cost reductions to offset lower sales volumes?

Given the significant drop in other income, are there changes in the company's investment portfolio or interest rate environments that investors should monitor for future non-operating gains?

More News on Mercury Laboratories

1 Year Returns:-9.00%